NYSE Shariah screener · October 2026
Is GSK plc (GSK) Halal?
GSK plc · NYSE: GSK · Healthcare
The short answer
Yes - GSK plc (GSK) passes this Shariah stock screen at all three gates. GSK, the Brentford-based global biopharma company, earns its revenue from specialty medicines, vaccines, and general medicines (FY2025 turnover 32,667 million pounds) - none of which involve alcohol, tobacco, gambling, weapons, adult entertainment, pork, or conventional finance. The financial ratios pass: gross debt of 17,859 million pounds is about 24.0% of its ~74.53B pound market cap (LSE, October 2026), below the ~33% ceiling, and finance income of 169 million pounds is about 0.52% of turnover, below the 5% ceiling. This is a factual screen, not a religious ruling - consult a qualified scholar for personal rulings.
Gate 1 — Business activity: PASS
GSK plc (NYSE: GSK), based in Brentford, UK (registered in England & Wales No. 3888792), is a global biopharma company: specialty medicines, vaccines, and general medicines. Its vaccine portfolio covers meningitis, shingles, flu, polio, measles and more; specialty areas include respiratory, antiviral, oncology, immunology, and HIV (ViiV Healthcare). Business-screen implication (factual): biopharma - no alcohol, tobacco, gambling, weapons, adult entertainment, pork, or conventional finance. (The Haleon consumer-health business was spun off in 2022 - background only.) Gate 1 passes. Facts only.
Gate 2 — Debt and cash: PASS
Per GSK's Annual Report 2025 (approved by the Board March 4, 2026; pound millions), gross debt at December 31, 2025 was 17,859 million pounds (net debt 14,453 million pounds after cash and liquid investments of 3,406 million pounds). Against a market cap of about 74.53B pounds (LSE-quoted, ~October 2026; sanity check: 4,075.4M voting shares x 18.60 pounds (LSE) = about 75.8B pounds; americanbankingnews: $101.70B, September 2026), debt / market cap is about 24.0% - below the ~33% ceiling. Gate 2 passes. Facts only.
Gate 3 — Non-compliant income: PASS
Per GSK's Annual Report 2025 (pound millions), Finance income (Note 11) was 169 million pounds (2024: 122 million pounds) against Turnover (Note 6) of 32,667 million pounds = about 0.52% of turnover - below the 5% non-compliant income ceiling. Zoya's GSK page independently publishes interest income of 56,000,000 pounds (0.17% of its 'combined total' revenue methodology; the Annual Report's 169 million pound finance income is primary here). Finance expense (Note 12) was 701 million pounds. Gate 3 passes. Facts only.
Key figures used
- Business: global biopharma (HQ Brentford, UK) - specialty medicines, vaccines (meningitis, shingles, flu, polio, measles), general medicines; specialty areas: respiratory, antiviral, oncology, immunology, HIV (ViiV Healthcare); Haleon consumer health spun off 2022
- FY2025 (Annual Report 2025, approved Mar 4, 2026; pound millions): turnover 32,667M (Note 6); finance income 169M (Note 11); finance expense 701M (Note 12); operating profit 7,932M (Note 8); profit attributable to shareholders 5,716M
- Debt: gross debt 17,859M pounds (Dec 31, 2025; net debt 14,453M after cash and liquid investments 3,406M) - about 24.0% of ~74.53B pound market cap (LSE, Oct 2026), below the ~33% ceiling
- Interest income: finance income 169M pounds - about 0.52% of 32,667M pounds turnover, below the 5% ceiling (Zoya: 56M pounds, 0.17% on its combined-total methodology)
- No haram segments: biopharma - no alcohol, tobacco, gambling, weapons, adult entertainment, pork, or conventional finance
- Third-party screeners: Zoya covers (page garbled - data only, no PASS/FAIL quote); Musaffa Academy '20 Halal Stocks in the UK by Market Cap' lists GSK as Halal (Jun 2024; bonus context, not a per-ticker rating); ShariaPortfolio - no coverage found
- Material: Q2 2026 earnings (Jul 28, 2026): EPS $1.36 vs $1.27 consensus, revenue $11.14B (+5.3% YoY); FY2026 guidance 4.900-5.000 EPS; dividend raised to $0.4515/share quarterly (paid Oct 8, 2026; $1.81 annualized, ~3.6% yield); 2B pound share buyback (18-month programme); ViiV Healthcare restructuring (Jan 2026); FY2025 acquisitions: IDRx, BP Asset IX, Cellphenomics GmbH (1,692M pounds)
- Listing: NYSE-listed sponsored ADR (ticker GSK; 2 ordinary shares per ADR; CUSIP 37733W105); live quote $47.18 Oct 2, 2026 - no delisting
Frequently asked questions
What does GSK do?
GSK plc (NYSE: GSK), based in Brentford, UK (registered in England & Wales No. 3888792), is a global biopharma company: specialty medicines, vaccines, and general medicines. Its vaccine portfolio covers meningitis, shingles, flu, polio, measles and more; specialty areas include respiratory, antiviral, oncology, immunology, and HIV (ViiV Healthcare). Its shares trade on the NYSE as a sponsored ADR (ticker GSK); each ADR represents two ordinary shares (CUSIP 37733W105; DR ISIN US37733W1053). In FY2025 (year ended December 31, 2025) it reported turnover of 32,667 million pounds. (The Haleon consumer-health business was spun off in 2022.)
Why does GSK pass this Shariah stock screen?
GSK passes all three gates of this Shariah stock screen. Gate 1 (business activity): biopharma - specialty medicines, vaccines, and general medicines involve no alcohol, tobacco, gambling, weapons, adult entertainment, pork, or conventional finance - a clean business. Gate 2 (debt): gross debt of 17,859 million pounds is about 24.0% of its ~74.53B pound market cap (October 2026), below the ~33% ceiling. Gate 3 (non-compliant income): finance income of 169 million pounds is about 0.52% of FY2025 turnover (32,667 million pounds), below the 5% ceiling. Result: PASS. This is a factual screen, not a religious ruling - consult a qualified scholar for personal rulings.
What is GSK's interest-bearing debt ratio?
Per GSK's Annual Report 2025 (approved by the Board March 4, 2026; pound millions), gross debt at December 31, 2025 was 17,859 million pounds (net debt 14,453 million pounds after cash and liquid investments of 3,406 million pounds). Against a market cap of about 74.53B pounds (LSE-quoted, ~October 2026; sanity check: 4,075.4M voting shares x 18.60 pounds (LSE) = about 75.8B pounds; americanbankingnews: $101.70B, September 2026), debt / market cap is about 24.0% - below the ~33% ceiling. Gate 2 passes. Facts only.
How much interest income does GSK earn?
Per GSK's Annual Report 2025 (pound millions), Finance income (Note 11) was 169 million pounds (2024: 122 million pounds) against Turnover (Note 6) of 32,667 million pounds = about 0.52% of turnover - below the 5% non-compliant income ceiling. Zoya's GSK page independently publishes interest income of 56,000,000 pounds (0.17% of its 'combined total' revenue methodology; the Annual Report's 169 million pound finance income is primary here). Finance expense (Note 12) was 701 million pounds. Gate 3 passes. Facts only.
Do Zoya, Musaffa, or ShariaPortfolio cover GSK?
Zoya covers GSK at zoya.finance/stocks/gsk (also zoya.finance/stocks/glaxf): its auto-generated FAQ page is garbled/contradictory (one line reads 'Shariah-compliant and therefore considered halal,' another 'Shariah-compliant and therefore not considered halal'), so no clean Zoya PASS/FAIL can be quoted - only coverage and underlying data are reported here (Zoya publishes FY2025 revenue of 32,667,000,000 pounds and interest income of 56,000,000 pounds, 0.17%). Musaffa: no per-stock musaffa.com/stock/GSK page was found; bonus context (not a per-ticker rating): Musaffa Academy's '20 Halal Stocks in the UK by Market Cap' lists GSK plc as Halal (June 2024). ShariaPortfolio: no public per-stock GSK coverage was found - honestly reported as no coverage found, not invented.
Sources
- GSK plc Annual Report 2025 (approved by the Board March 4, 2026; pound millions; registered in England & Wales No. 3888792): Turnover (Note 6) 32,667M; Finance income (Note 11) 169M; Finance expense (Note 12) 701M; Operating profit (Note 8) 7,932M; gross debt 17,859M; cash and liquid investments 3,406M; net debt 14,453M; 4,075,425,537 voting rights ex-treasury (Form 6-K, Jan 5, 2026)
- Zoya GSK stock page (2026): coverage of GSK; publishes FY2025 revenue 32,667,000,000 pounds and interest income 56,000,000 pounds (0.17% of combined total); auto-generated FAQ text is garbled/contradictory - data only, no PASS/FAIL quoted
- Musaffa Academy '20 Halal Stocks in the UK by Market Cap' (June 2024): lists GSK plc (GSK.L) as Halal - bonus context, not a per-ticker rating
- Finnhub GSK live market data (Oct 2, 2026): NYSE (XNYS), price ~$47.18 - live quote, no delisting
Screened 2026-10-02 from published company figures and market data. Figures change; this page is educational, not financial advice and not a religious ruling.
Screened with our two-gate Shariah screening methodology (business-activity gate, then AAOIFI-style financial ratios).